Overview of phosphodiesterase 5 inhibition in erectile dysfunction
- 6 November 2003
- journal article
- review article
- Published by Elsevier
- Vol. 92 (9) , 9-18
- https://doi.org/10.1016/s0002-9149(03)00824-5
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Sildenafil in patients with cardiovascular diseaseThe American Journal of Cardiology, 2003
- Cardiovascular effects of tadalafilThe American Journal of Cardiology, 2003
- Cardiovascular effects of tadalafil in patients on common antihypertensive therapiesThe American Journal of Cardiology, 2003
- Vardenafil, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With DiabetesDiabetes Care, 2003
- The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trialInternational Journal Of Impotence Research, 2001
- On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunctionInternational Journal Of Impotence Research, 2001
- Phosphodiesterase 5 inhibitors and nitrergic transmission—from zaprinast to sildenafilEuropean Journal of Pharmacology, 2001
- Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panelThe American Journal of Cardiology, 2000
- Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 1998
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998